SCHEDULE 13G/A: BlackRock Amends Stake in BioMarin Pharmaceutical, Reports 10.8% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 10.8% of BioMarin Pharmaceutical Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 12 to Schedule 13G regarding its beneficial ownership in BioMarin Pharmaceutical Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 20,620,179 shares of BioMarin Pharmaceutical Inc. Common Stock.
- This represents 10.8% of the total outstanding common stock of BioMarin Pharmaceutical Inc.
- BlackRock holds sole voting power over 19,431,566 shares and sole dispositive power over 20,620,179 shares.
- No shared voting or dispositive power is reported by BlackRock.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., is identified as an entity that beneficially owns 5% or greater of the outstanding shares of the security class.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of an ownership stake by an institutional investor, not an announcement of company performance or strategic changes. It reflects a routine regulatory filing.
Industry Context
This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive ownership stake in BioMarin Pharmaceutical Inc. Such filings are common for large asset managers who hold significant positions across numerous public companies as part of their diversified investment strategies, reflecting their portfolio allocations rather than specific strategic moves related to the issuer's industry.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on a significant institutional holding, confirming BlackRock's continued passive investment in BioMarin Pharmaceutical Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney, which was expressly revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-04-29 | Date of filing (signature date) of the Schedule 13G Amendment No. 12. |
Keywords
BlackRock, BioMarin Pharmaceutical Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.